NCT05660135View on ClinicalTrials.gov

Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia

Active, not recruitingOBSERVATIONAL
Enrollment

4,000

Participants

Timeline

Start Date

June 20, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2025

Conditions
HypertensionDyslipidemias
Interventions
DRUG

Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca

Olomax Tab 20/5/5mg Olomax Tab 20/5/10mg Olomax Tab 40/5/5mg Olomax Tab 40/5/10mg

Trial Locations (1)

Unknown

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY